Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of treatment of pain, Charcot-Marie-Tooth disease, urinary incontinence, multiple sclerosis and arrhythmia.
Erasca Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant targeting moiety through a linker reported to be useful for the treatment of cancer.
Shanghai Allist Pharmaceuticals Co. Ltd. has patented nitrogen-containing heterocyclic compounds acting as GTPase KRAS, particularly G12D or G12V mutant, inhibitors reported to be useful for the treatment of cancer.
Work at Hangzhou Highlightll Pharmaceutical Co. Ltd. has led to the development of tyrosine-protein kinase JAK1, JAK2 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Cytokinetics Inc. has disclosed fast skeletal muscle myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, spinal cord injury, limb girdle muscular dystrophy, stroke, tendinitis and tremor, among others.
RSS